Phreesia, Inc. (NYSE:PHR – Get Free Report) General Counsel Allison C. Hoffman sold 3,496 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $29.72, for a total value of $103,901.12. Following the completion of the sale, the general counsel now directly owns 142,630 shares in the company, valued at approximately $4,238,963.60. This represents a 2.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Phreesia Trading Down 0.9 %
Phreesia stock opened at $28.20 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. Phreesia, Inc. has a one year low of $17.07 and a one year high of $30.53. The stock has a market capitalization of $1.64 billion, a PE ratio of -19.18 and a beta of 0.96. The business’s fifty day moving average is $27.29 and its 200 day moving average is $23.84.
Phreesia (NYSE:PHR – Get Free Report) last posted its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The company had revenue of $106.80 million for the quarter, compared to the consensus estimate of $106.33 million. During the same quarter in the prior year, the company earned ($0.58) earnings per share. Phreesia’s revenue was up 16.6% on a year-over-year basis. On average, sell-side analysts predict that Phreesia, Inc. will post -1.1 EPS for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of equities research analysts have recently commented on the company. Citigroup increased their target price on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. JMP Securities reissued a “market outperform” rating and issued a $30.00 target price on shares of Phreesia in a research note on Tuesday, December 10th. Needham & Company LLC reissued a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research note on Friday, January 10th. Truist Financial increased their target price on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Finally, Royal Bank of Canada raised Phreesia from a “sector perform” rating to an “outperform” rating and increased their target price for the stock from $24.00 to $32.00 in a research note on Wednesday, January 8th. Thirteen equities research analysts have rated the stock with a buy rating, According to MarketBeat, Phreesia currently has an average rating of “Buy” and a consensus price target of $31.15.
View Our Latest Stock Report on PHR
About Phreesia
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Featured Stories
- Five stocks we like better than Phreesia
- Pros And Cons Of Monthly Dividend Stocks
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Investing in the High PE Growth Stocks
- DuPont’s Electronics Spinoff: The Start of Something Big
- 3 REITs to Buy and Hold for the Long Term
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.